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ABSTRACT 
 
 
SYNERGISTIC EFFECTS OF DELTA- δ-TOCOTRIENOL AND XANTHORRHIZOL 
IN PROSTATE CANCER CELLS 
 
by 
C. Rebecca Madhani 
 
Background: Approximately one in seven American men will be diagnosed with 
prostate cancer during their lifetime. The mevalonate pathway produces essential 
intermediates for the post-translational prenylation and dolichylation of growth-
associated proteins including Ras, nuclear lamins and growth factor receptors.  
Dysregulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the 
rate-limiting enzyme of the mevalonate pathway, in prostate cancer cells supports tumor 
growth and therefore can be targeted for prostate cancer prevention and therapy. Previous 
studies have shown that isoprenoids including tocotrienols and xanthorrhizol suppress the 
growth of prostate cancer cells with concomitant downregulation of HMG CoA 
reductase. 
Objective:  To determine the synergistic effects of d-δ-tocotrienol and xanthorrhizol on 
growth of human DU-145 prostate carcinoma cells. 
Methods:  DU-145 cells were incubated with d-δ-tocotrienol and xanthorrhizol, 
individually and in blends, for 72 hours before viable cells were quantified by CellTiter 
96® Aqueous One Solution. The impacts of these compounds, individually and in 
combination, on cell cycle distribution and the 
expression of cell cycle related proteins in DU-145 cells were evaluated by flow 
cytometry and Western-blot in follow-up studies. 
Statistical analysis: All experiments were repeated 3 times. One-way analysis of 
variance (ANOVA) was performed to assess the differences between groups using Prism
Ⓡ 4.0 software (GraphPad Software Inc., San Diego, CA). Differences in means was 
assessed using Tukey’s test. Levels of significance are indicated as P < 0.05.  
Results: Blends of d-δ-tocotrienol and xanthorrhizol showed greater inhibition of cell 
growth than those of individual compounds. Current results did not show a significant 
change in cell cycle distribution or down regulation of Cdk4 and cyclin D1 with the 
combination of compounds. The level of procaspase-3 for apoptosis initiation was also 
not altered. 
Conclusion: Further studies are warranted to confirm these initial findings and 
understand the mechanisms underlying the combined effect of d-δ-tocotrienol and 
xanthorrhizol on cell proliferation.
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CHAPTER I 
 
SYNERGISTIC EFFECTS OF DELTA- δ-TOCOTRIENOL AND XANTHORRHIZOL 
IN PROSTATE CANCER CELLS 
 
Introduction 
 Approximately one in seven American men will be diagnosed with prostate 
cancer during their lifetime. In 2017, the Centers for Disease Control and Prevention 
reported 161,360 North American men diagnosed with prostate cancer and 26,730 deaths 
from prostate cancer. (1)  Prostate cancer is currently treated with methods such as 
chemotherapy, radiation, and surgery. Radiation and surgery may cause side effects such 
as infections, impotence, or bladder and bowel problems. (2) Chemotherapy is 
accompanied by disconcerting symptoms including loss of appetite, mouth sores, fatigue, 
nausea, vomiting, diarrhea, and hair loss. In addition, common chemotherapy agents 
including Docetaxel, Mitoxantrone, and Estramustine may put patients at risk for 
peripheral neuropathy, leukemia, and blood clots, respectively. (3) Therefore, alternative 
therapies are necessary for the treatment of prostate cancer. 
Two dietary factors that could potentially serve as therapeutic agents for prostate 
cancer are d-δ-tocotrienol and xanthorrhizol. d-δ-Tocotrienol, a minor form of vitamin E, 
has been found to decrease cancer cell proliferation by inhibiting HMG-CoA reductase in 
the mevalonate pathway, thereby preventing prenylation or dolichylation of growth-
related proteins. (4) In addition, d-δ-tocotrienol has been associated with 
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cell cycle arrest in the G1 phases with a concomitant inhibition of Cdk4 and caspase-3 
activation and apoptosis in melanoma cells. (5) Xanthorrhizol is a bisabolane-type 
sesquiterpene that has also exhibited anti-cancer effects by inducing cell cycle arrest 
through decreased expression of Cyclin D1 and Cdk4, and apoptosis by activation of 
procaspases 3 & 9 in colon cancer cells. (6) 
 
Hypothesis and Specific Aims 
Hypothesis: d-δ-Tocotrienol and xanthorrhizol synergistically suppress the 
proliferation of DU-145 prostate carcinoma cells by inducing cell cycle arrest and 
apoptosis. 
Specific aim 1: To determine the effects of d-δ-tocotrienol and xanthorrhizol, 
individually and in combination, on prostate cancer cell proliferation. 
Specific aim 2: To determine the effects of d-δ-tocotrienol and xanthorrhizol, 
individually and in combination, on cell cycle progression and cell cycle-related 
proteins of prostate cancer cells. 
Specific aim 3: To determine the effects of d-δ-tocotrienol and xanthorrhizol, 
individually and in combination, on an apoptosis-related protein, procaspase-3, of 
prostate cancer cells. 
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CHAPTER II 
 
Literature Review 
Metabolic Regulation and Cancer Therapies 
The RB pathway plays a vital role in cell proliferation by activating and 
suppressing growth related factors, mediating entry of cells into the cell cycle. The RB 
pathway consists of five protein families including D-type cyclins, CDKN, (Ink4a), E2F-
transcription factors, cyclin-dependent protein kinases (e.g. Cdk4, Cdk6) and RB-family 
pocket of proteins. (7) Cdk4 and Cdk6 are catalytic components that bind to D-cyclins to 
form active kinase complexes and initiate cell progression through the cell cycle. (8) 
Ink4a proteins inhibit the activity of Cdk4 and Cdk6 by competing with cyclin D1 to 
suppress creation of the active cyclin-D1/Cdk4/6 kinase complex, which is activated 
during normal cell cycle entry and proliferation. (9) Other cellular targets of the D-
cyclin/Cdk4/6 complexes are RB-proteins, which control chromatin structures and E2F-
transcription factor activities. (8)  
The E2-factor is a family of transcription factors that are downstream effectors of 
the RB pathway. E2F play important roles in entry of the S phase of the cell cycle (10) 
and p53-dependent and p53-independent apoptosis. (11) RB-pocket proteins can be 
directed to E2F-regulated promoters, thereby inhibiting transcription by suppressing E2F 
transactivation. The D-cyclin/Cdk4/6 complex can phosphorylate RB-pocket proteins and 
disrupt RB-E2F interaction, prompting activation of E2F-regulated gene expression. In 
cancer cells, the RB-pathway is modified to promote deregulated tumor cell proliferation 
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by failing to suppress E2F activity. Consequently, the D-cyclin/Cdk4/6 kinase 
complex stimulates tumor cell proliferation, however Ink4a proteins operate as tumor 
suppressors by inhibiting D-cyclins. (7) 
Apoptosis is a regulated cellular suicide that is necessary to remove damaged 
cells. An accumulation of evidence has shown mitochondria to be the major organelles 
involved in apoptosis, through processes including DNA damage, growth factor down 
regulation, and chemotherapeutic drugs. (12) Apoptosis is promoted through increased 
E2F activity, which enhances the expression of pro-apoptotic genes such as caspases.  
Caspases are cysteine proteases that are activated in apoptotic cells. Caspases 2, 8, and 9 
are initiator caspases that cleave downstream effectors caspases 3, 6, and 7. Effector 
caspases execute apoptosis by cleaving cellular proteins. (13)  
The mevalonate pathway plays important roles in cell proliferation and cell death. 
Intermediates of the mevalonate pathway, including farnesyl pyrophosphate (FPP) and 
geranylgeranyl pyrophosphate (GGPP), are required for the prenylation, membrane 
attachment, and biological activities of many growth-related proteins and dolichylation of 
growth factor receptors. Among the growth-associated proteins that are prenylated are the 
nuclear lamins and the small GTPases, including the Ras protein, that are involved in 
signaling regulating cell division. (14) 
The importance of mevalonate pathway intermediates in cell proliferation and cell 
death renders the pathway a useful target for prostate cancer therapy. One approach is to 
suppress the rate-limiting enzyme, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase, of the pathway. (15) In eukaryotic cells, HMG CoA reductase is regulated at 
multiple levels, including sterol-mediated transcriptional downregulation and non-sterol-
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mediated posttranscriptional downregulation; the latter includes ubiquitination and 
proteasome-mediated degradation of HMG CoA reductase. (7) One class of HMG CoA 
reductase inhibitors is statins. Statins are competitive inhibitors of HMG CoA reductase 
and are widely prescribed for their hypocholesterolemic effect. (14) 
 
Tocotrienol and Cancer Inhibition 
Tumor cell proliferation is suppressed by down regulation of HMG-CoA 
reductase, which is the committed step for the biosynthesis of sterols such as cholesterol 
through the mevalonate pathway. In contrast, tocotrienol has been shown to down 
regulate HMG CoA reductase, thereby inhibiting tumor cell proliferation. (14) 
In addition to the statins mentioned above, tocotrienols are another class of HMG 
CoA suppressors. Tocotrienols, a minor form of vitamin E, include four chemical forms 
(ɑ-, β-, ɣ-, and δ-tocotrienol). Tocotrienols vary by the number and position of methyl 
groups in the polar head of the molecules.  Tocotrienol is derived from dietary sources 
including palm oil, red annatto seeds, grape seed oil, flaxseed oil, buckthorn berry, rye, 
oat, and barley. Tocotrienol studies began in the early 1990’s and focused on regulation 
of cholesterol production via post-transcriptional suppression of HMG CoA reductase. 
(16) Tocotrienols have been found to mimic sterols by promoting ubiquitination and 
degradation of HMG-CoA reductase. (4) Over the past two decades, tocotrienol has been 
found to suppress the proliferation of tumor cells originated from various tissues, 
including colon, breast, prostate, skin, liver, lung, lymph gland, cervix, and nerve. (17)  
 Har et al. examined the effects of tocotrienol in BNL CL.2 normal liver cells and 
BNL 1ME A.7R.1 liver cancer cells. Tocotrienols appeared to have a greater effects in 
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liver cancer cells compared to normal liver cells in all experiments. Tocotrienol 
significantly reduced cell viability of liver cancer cells in a dose-dependent manner. 
Elevated caspase-3 activity was found in liver cancer cells in a time dependent manner 
following 9, 12, and 24 hour treatments of tocotrienol. Finally, 24-hour tocotrienol 
treatment induced DNA fragmentation in liver cancer cells compared to untreated cells. 
These data suggest that tocotrienol decreases viability in 1ME A.7R.1 liver cancer cells 
through apoptotic activity of caspase-3. (18) 
Fernandes et al. looked at the effect of d-δ-tocotrienol in A2058 and A375 human 
melanoma cells. d-δ-Tocotrienol caused a dose-dependent inhibition of cell proliferation 
in both A2058 and A375 cell lines. Cell cycle analysis demonstrated significant increases 
in the percentage of cells in the G
1
 phase for both cell lines after treatment with d-δ-
tocotrienol. d-δ-Tocotrienol (24 μM) raised the percentage of A2058 cells in the G1 
phase from 46% to 63% (P < 0.05). Concomitantly, S% decreased from 35% to 20% (P < 
0.05). G1 arrest was also seen in A375 cells treated with 33 μM d-δ-tocotrienol. G1 arrest 
was congruent with a significant decrease in expression of Cdk4, a vital catalyst in the 
transition from G1 to S phase, for both cell lines. (5) 
A concentration-dependent cleavage of procaspase-3 was initiated by d-δ-
tocotrienol in A2058 cells using western blot analysis. Cleavage of procaspase-3 is shown 
through lighter bands in western blot analysis. These data suggest that d-δ-tocotrienol 
induces cell cycle arrest in A2058 and A375 cells and initiates caspase-3 activation and 
apoptosis in A-2058 human melanoma cells. (5) 
Srivastava and Gupta found significant growth inhibition of DU-145 human 
prostate cancer cells induced by tocotrienol-rich fraction (TRF). TRF composition was  
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14.77% α-tocotrienol, 33.97% γ-tocotrienol, 26.11% d-δ-tocotrienol, 18.10% α-
tocopherol, and 7.05% of other tocotrienol-like compounds. DU-145 cell growth 
decreased by 17.9%, 20.1%, 46.5%, 78.3%, and 79.8%, after treatment with 5, 10, 20, 40, 
and 80 µg/ml of TRF, respectively. In addition, TRF caused a dose-dependent increase of 
the percentage of DU-145 cells in the G0/G1 phase, compared to the control. A 
concomitant decrease in the percentage of cells in the S phase of cell cycle was shown, 
compared to the control. These data suggest that TRF caused a dose-dependent decrease 
in cell growth and increase in cell cycle arrest at the G0/G1 phase in DU-145 cells. (19) 
 
Xanthorrhizol and Cancer Inhibition 
Sesquiterpenes are a class of isoprenoids that have been shown to suppress the 
mevalonate pathway and inhibit the biosynthesis of essential intermediates required for 
the function of growth related proteins such as Cdk4. Consequently, sesquiterpene-
mediated downregulation of HMG CoA reductase induces cell cycle arrest and initiates 
apoptosis. (14) 
Xanthorrhizol is a sesquiterpene derived from Curcuma xanthorrhiza rhizome, 
also known as Javanese turmeric. Xanthorrhizol is native to Indonesia and has exhibited a 
variety of health benefits, including anti-inflammatory, antimicrobial, antioxidant, 
hyperglycemic, antihypertensive, antiplatelet, nephroprotective, estrogenic, and 
anticancer properties. It has been speculated that xanthorrhizol suppresses carcinogenesis 
by delivering cytotoxic effects from its phenol group. Xanthorrhizol’s anti-cancer effects 
have been associated with its contribution to apoptosis and cell cycle arrest. (6) 
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Cheah et al. found a concentration-dependent growth inhibition in MDAMB-231 
human breast cancer cells, caused by 48 hour treatments of xanthorrhizol. Apoptotic 
levels of MDAMB-231 cells was measured using an apoptotic index after 24 hours of 
treatment with xanthorrhizol. A significant increase (p<0.005) of apoptosis was found, in 
a dose-dependent manner. Finally, caspase activity of MDAMB-231 cells after 
xanthorrhizol treatment was also assessed, which found a significant increase (p<0.005) 
in caspase-3 activity compared to control cells. These data suggest that xanthorrhizol 
induced growth inhibition and apoptosis by activation of caspase-3 in MDAMB-231 
human breast cancer cells. (20) 
 Kang et al. found that 24-hour treatments of xanthorrhizol inhibited growth and 
increased percentage of HCT-116 human colon cancer cells at the G0/G1 phase of the 
cell cycle, compared to control. Percentage of HCT-116 cells in the S phase also 
decreased compared to the control. Concomitantly cyclin D1 and Cdk4 were 
downregulated in a time- and dose-dependent manner. As previously mentioned, cyclin 
D1 and Cdk4 form the active kinase complex for transition of cells from the G1 to S 
phases of cell cycle. This suggests cell cycle arrest of the G0/G1 phase induced by 
xanthorrhizol by down regulation of cyclin D1 and Cdk4. (21) 
Kang et al. also found evidence of apoptosis through DNA fragmentation, 
activation of procaspases 3 & 9, release of cytochrome c, and cleavage of poly-(ADP-
ribose) polymerase. DNA fragmentation was determined using an agarose gel 
electrophoresis with 24 and 48 hour treatments of xanthorrhizol. Apoptosis was detected 
in a time- and dose-dependent manner. Apoptosis was also detected using western blot 
analysis. Cleaved caspase-3 was increased in a dose-dependent manner after 24 and 48 
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hour xanthorrhizol treatments. Additionally, expression of procaspase-3 was decreased in 
a time- and dose-dependent manner. (21) 
Handayani et al. examined the effects of xanthorrhizol in HepG2 human liver 
cancer cells. IC50 values were used to conduct cytotoxicity assays; increasing 
concentrations of xanthorrhizol was found to inhibit HepG2 cell growth in a dose 
dependent manner. Apoptotic levels of HepG2 cells was measured using an apoptotic 
index after 24, 48, and 72 hours of treatment with xanthorrhizol. The percentage of 
apoptotic cells was increased to more than 70% in all treatment groups compared to the 
less than 5% in the control. Western blot analysis of apoptosis-related proteins after 24, 
48, and 72 hour treatments of xanthorrhizol showed a time-dependent decrease in 
procaspase-3 and increased expression of caspase-3. (22) 
In summary, tocotrienol has shown anti-proliferative effects in BNL 1ME A.7R.1 
liver (18), A2058 and A375 melanoma (5), and DU-145 prostate (19) cancer cells. 
Tocotrienol induced apoptotic events in BNL 1ME A.7R.1 liver cells (18) and A2058 
melanoma cells (5). Tocotrienol also induced cell cycle arrest in DU-145 prostate cancer 
cells (19) and A2058 and A375 melanoma cells (5). Xanthorrhizol has shown anti-
proliferative effects in MDAMB-231 breast (20), HCT-116 colon (21), and HepG2 liver 
(18) cancer cells, but not prostate cancer. Xanthorrhizol has exhibited apoptotic events in 
MDAMB-231 breast (20) and HepG2 liver (18) cancer cells, and both apoptosis and cell 
cycle arrest in HCT-116 colon cancer cells (21). No studies to date have looked at the 
synergistic effects of tocotrienol and xanthorrhizol in prostate cancer cells.
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CHAPTER III 
Methods and Procedures 
Materials 
Human DU-145 prostate carcinoma cells were received as a gift from the Biology 
Department at Georgia State University Biology and were used in all procedures. All 
supplies needed for cell culturing were purchased from Fisher Scientific, Inc. (Pittsburgh, 
PA) and Thermo Scientific (Waltham, MA). Xanthorrhizol and d-δ-tocotrienol were 
received as a gift from American River Nutrition, Inc. (Hadley, MA). 
Cell Culture 
DU-145 cells were cultured in Roswell Park Memorial Institute (RPMI-1460) 
media and supplemented with 10% Fetal Bovine Serum (FBS), 1% penicillin-
streptomycin, and 0.8% gentamicin in 25 cm2 flasks. Cells were then incubated for 48 
hours at 37oC in a humidified atmosphere of 5% CO2. At 48 hours, cells were subcultured 
into a 175 cm2 flask, grown to 80 - 90% confluence, and then prepared according to 
experimental procedure. Nine treatments were used for each experiment, as follows: 
control (C), d-δ-tocotrienol 5 µM (T5), d-δ-tocotrienol 10 µM (T10), xanthorrhizol 16.25 
µM (X16.25), xanthorrhizol 32.5 µM (X32.5), d-δ-tocotrienol 5 µM & xanthorrhizol 
16.25 µM (T5/X16.25), d-δ-tocotrienol 5 µM & xanthorrhizol 32.5 µM (T5/X32.5), d-δ-
tocotrienol 10 µM & xanthorrhizol 16.25 µM (T10/X16.25), d-δ-tocotrienol 10 µM & 
xanthorrhizol 32.5 µM (T10/X32.5). Each treatment was dissolved in ethyl alcohol, with 
the control containing ethyl alcohol only. 
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Cell Proliferation 
Cell titer was performed to quantify the effects of d-δ-tocotrienol, xanthorrhizol, 
and a combination of both on DU-145 cell proliferation. Human prostate cancer (DU-
145) cells were cultured as previously described and seeded in 96-well plates at 1,500 
cells per well.  Cells were treated at 0.1% volume for 72 hours with respective treatments 
of xanthorrhizol and d-δ-tocotrienol.  At 72 hours, complete RPMI media was aspirated 
from wells; cells were then washed with 1x Hank’s Balanced Salt Solution (1x HBSS), 
and refreshed with 100 µL serum-free RPMI media and 20 µL Cell Titer 96® Aqueous 
One Solution. Cells were then incubated for 2 hours at 37°C, 5% CO2.  At 2 hours, the 
plate was measured using a Biotek, Synergy HT plate reader; results were analyzed using 
the Gen5TM software from Biotek® Instruments, Inc. (Winooski, VT, USA).  
Cell Cycle Analysis 
Xanthorrhizol and d-δ-tocotrienol were tested for their effects on cell cycle 
distribution in DU-145 cells. Cells were seeded in 25 cm2 flasks (Becton Dickinson 
Labware, Franklin Lakes, NJ) at 1.5x106 cells per flask with 3 mL RPMI medium per 
flask and incubated for 24 hours. At 24 hours, medium was aspirated and replaced with 
fresh medium containing respective treatments of xanthorrhizol and d-δ-tocotrienol. After 
24 hours of incubation, cells were harvested by trypsinization and pelleted by 
centrifugation at 13,000 x g for 5 minutes. Cell pellets were then fixed in 1 mL of 70% 
ethanol at -20 degrees Celsius overnight. In preparation for analysis, cells were washed 
twice with a 1x Phosphate Buffer Solution (1x PBS) and centrifuged at 5 minutes after 
each wash. Cells were re-suspended in 500 µL of 1x PBS containing RNase A (Sigma-
Aldrich) and incubated at 37 degrees Celsius without light for 30 minutes. One hundred 
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µL of a PBS-TritonX100-propidium iodide solution was added to each sample and held 
in the dark, at room temperature for 15 minutes. Stained cell samples were divided into 
200 µL aliquots and analyzed for DNA content using a BD LSR Fortessa flow cytometer 
(BD Biosciences, San Jose, CA, USA). The distribution of cells in the G1, S, and G2 
phases of the cell cycle was determined using FCS Express software (De Novo Software, 
Glendale, CA). 
Western Blot Analysis 
Western-blot was performed to examine the proteins Cdk4, Cyclin D-1, and 
Procaspase-3. Protein concentration of DU-145 cells treated with respective treatments of 
xanthorrhizol and d-δ-tocotrienol was determined using a bicinchoninic acid protein 
assay kit (Pierce, Rockford, IL, USA). Treatment samples containing 10 µg of protein 
was mixed with 4x Laemmli Sample Buffer (Bio-Rad Laboratories, Hercules, CA, USA) 
at a 1:1 ratio (v/v) and β-Mercaptoethanol before loading into a 12% SDS-
polyacrylamide gel. Gels were then loaded onto a Mini PROTEAN Tetra electrophoresis 
unit (Bio-Rad Laboratories) and run at 100 volts (V) for 10 minutes, and 150 V for 1.5 
hours. Proteins were transferred from the gel onto an Immun-Blot Polyvinylidene 
difluoride (PVDF) membrane (Bio-Rad Laboratories) with a Trans Blot© Turbo™ 
Transfer System (Bio-Rad Laboratories) at 25 V and 1 amp (A) for 30 minutes. 
Polyvinylidene difluoride membranes were then be incubated in blocking solution (5% 
non-fat dry milk in 1x PBS) and shaken at room temperature for 20 minutes. After 
blocking, membranes were rinsed with Phosphate Buffered Saline containing 0.1% 
Tween-20 solution (PBST), twice for five minutes and once for ten minutes. Membranes  
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were then incubated with a 1:1000 dilution of PBST and monoclonal antibodies to 
beta-actin at 4 degrees Celsius on a rocker overnight.  
After overnight incubation, membranes were washed with PBST twice for five 
minutes and once for ten minutes and incubated with a 1:1000 dilution of PBST and 
secondary antibody (horseradish peroxidase linked; Cell Signaling Technology) for one 
hour. After a third wash period, membranes were exposed to a Super Signal West Pico 
Chemiluminescence Kit (Pierce) and then photographed with an Image Quant LAS 4000 
system (GE Healthcare Life Sciences, Pittsburgh, PA). 
Membranes were incubated again with blocking solution for twenty minutes, 
washed three times, and incubated with primary antibodies of interest at 4 degrees 
Celsius on a rocker overnight. Antibodies included cyclin-dependent kinase-4 (Cdk4) 
(Santa Cruz Biotechnology, Santa Cruz, CA) and procaspase-3 (PC-3) (Santa Cruz 
Biotechnology) with a 1:500 PBST solution, and Cyclin-D1 (Cell Signaling Technology, 
Danvers, MA) with a 1:1000 PBST solution overnight. Membranes were washed again 
three times and incubated with PBST and respective secondary antibodies in a 1:1000 
dilution (Cdk4: mouse; Procaspase-3: mouse; Cyclin-D1: rabbit; horseradish peroxidase 
linked) for one hour at room temperature. Finally, membranes were washed three times, 
treated with the Super Signal Chemiluminescence solution, and imaged as described 
above.  
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Statistical Analysis 
All experiments were repeated 3 times. One-way analysis of variance (ANOVA) 
was performed to assess the differences between groups using PrismⓇ 4.0 software 
(GraphPad Software Inc., San Diego, CA). Differences in means was assessed using 
Tukey’s test. Values are mean ± standard error of the mean (SEM). Levels of significance 
are indicated as P < 0.05.  
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CHAPTER IV 
Results 
Cell proliferation of DU-145 cells was first analyzed using the predefined 
treatment groups. Figure 1 shows the cytotoxic effect of d-δ-tocotrienol and xanthorrhizol 
on DU-145 human prostate cancer cells. Proliferation of DU-145 cells treated with 5 µM 
of d-δ-tocotrienol (T5) and 10 µM of d-δ-tocotrienol (T10) and 32.5 µM of xanthorrhizol 
(X32.5) was 56 ± 37%, 67 ± 7%, and 43 ± 7%, respectively, of that of untreated cells. 
Xanthorrhizol treatment reduced cell proliferation to a level significantly different from 
that of untreated cells (P < 0.05). A combination of 5 μmol/L of d-δ-tocotrienol and 32.5 
μmol/L of xanthorrhizol (T5/X32.5) decreased cell proliferation to 17 ± 7% of that of 
untreated cells. The 83% inhibition of proliferation achieved by the combination is 
greater than the 44% (d-δ-tocotrienol) and 57% (xanthorrhizol) inhibitions induced by the 
two agents individually (P < 0.05). Similarly, the 81% inhibition of proliferation 
achieved by the combination of 10 μmol/L of d-δ-tocotrienol and 32.5 μmol/L of 
xanthorrhizol (T10/X32.5) is greater than the 33% (d-δ-tocotrienol) and 57% 
(xanthorrhizol) inhibitions (P < 0.05).  
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Figure 1. Suppression of DU-145 prostate carcinoma cell proliferation induced by 
d-δ-tocotrienol and xanthorrhizol. Cells were plated at a density of 1.5 x 103 cells/well in 
96-well plates with complete RPMI media. After 24 hours of incubation, wells were 
divided into respective treatment groups (6 replicates/group) and incubated for an 
additional 72 hours. Viable cell count was then determined using a CellTiter 96® 
Aqueous One Solution. Data are based upon 3 assays. Vertical bars represent percentage 
of viable cells according to respective treatments. Asterisks * and ** represent a 
significant difference between T10 and groups T10/X16.25 (P < 0.01), and T10/X32.5 (P 
< 0.001), respectively. Values are mean ± SEM, n = 18.  
 Cell cycle distribution of DU-145 cells was then evaluated (Fig. 2) to determine 
whether inhibition of cell proliferation induced by d-δ-tocotrienol and xanthorrhizol was 
attributed, at least in part, to cell cycle arrest. Percentage of cells in the G1 phase for 0  
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hour (when the treatment started) and control groups at 24 h was 44 ± 2% and 53 ± 4%, 
respectively. Cells treated with 5 μM of d-δ-tocotrienol (T5), 10 μM of d-δ-tocotrienol 
(T10), 32.5 μM of xanthorrhizol (X32.5), 5 μM of d-δ-tocotrienol and 32.5 μM of 
xanthorrhizol (T5/X32.5), and 10 μM of d-δ-tocotrienol and 32.5 μM of xanthorrhizol 
(T10/X32.5) exhibited G1 percentages of 46 ± 6%, 46 ± 3%, 46 ± 5%, 47 ± 7%, and 49 ± 
12%, respectively. The percentage of cells in the S phase for 0 hour and control groups 
was 32 ± 6% and 28 ± 3%, respectively. Cells treated with T5, T10, X32.5, T5/X32.5, 
and T10/X32.5 exhibited S phase percentages of 36 ± 9%, 37 ± 5%, 44 ± 10%, 34 ± 12%, 
and 35 ± 11%, respectively. The percentage of cells in the G2 phase for 0 hour and 
control groups was 24 ± 4% and 19 ± 6%, respectively. Cells treated with T5, T10, 
X32.5, T5/X32.5, and T10/X32.5 exhibited G2 phase percentages of 19 ± 11%, 18 ± 6%, 
9 ± 9%, 19 ± 11%, and 16 ± 6%, respectively. No significant differences in G1% were 
observed with any of the treatments. X32.5 significantly reduced the G2% as compared 
to untreated cells (P < 0.05), as noted by ***. Asterisks * and ** for G2 phase denote 
significant differences between groups X16 and X32, and X32 and T5/X16, respectively.  
 
 
 
 
 
 
 
 
18 
 
 
Figure 2. Cell Cycle Analysis 
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Figure 2. The impact of individual and combined effects of d-δ-tocotrienol and 
xanthorrhizol on the distribution of human DU-145 prostate cancer cells in the G1, S, and 
G2 phases of the cell cycle following 24 h of incubation. DU-145 cells were plated at a 
density of 1.5 x 106 cells per 25 cm2 flask with 3 ml media and incubated for 24 hours. 
Cells were then treated and incubated for 24 hours. After incubation, cells were 
trypsinized, stained with propidium iodide, and analyzed for cell cycle distribution using 
flow cytometry. Brackets in the S phase denotes a significant difference between T5 and 
T5/X16.25; brackets in the G2 phase denotes a significant difference between X32.5 and 
the control. Tukey’s multiple comparison test was used for repeated-measures analysis of 
variance. Values are mean ± SEM, n = 6. 
Figures 3a and 3b illustrate the impact of individual and combined treatments of 
d-δ-tocotrienol (T) and xanthorrhizol (X) on 24-h expression of Cdk4 and cyclin D1, 
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respectively, two regulatory proteins of the G1/S phase transition in the cell cycle of DU-
145 cells. Levels of Cdk4 were 97 ± 24%, 96 ± 39%, 76 ± 21%. 97 ± 40%, 91 ± 20% of 
that of control for cells treated with T5, T10, X32.5, T5/X32.5 and T10/X32.5, 
respectively. Levels for cyclin D1 were 128 ± 14%, 114 ± 16%, 112 ± 18%. 103 ± 32%, 
155 ± 34% of that of control cells for cells treated with T5, T10, X32.5, T5/X32.5 and 
T10/X32.5, respectively. No significant difference was observed between any groups. 
Figure 3c. illustrates the impact of d-δ-tocotrienol (T) and xanthorrhizol (X), 
individually and in combinations, on 24-h expression of procaspase-3 (PC-3), a pro-
apoptotic protein. Levels for PC-3 were 118 ± 15%, 91 ± 23%, 112 ± 25%, 77 ± 4%, 107 
± 84% of that of control cells for cells treated with T5, T10, X32.5, T5/X32.5 and 
T10/X32.5, respectively. No significant difference was observed between any groups. 
 
Figure 3. Western Blot Analysis 
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Figure 3. Representative blots showing the impact of d-δ-tocotrienol (T) and 
xanthorrhizol (X), individually and in combinations, on 24-h expression of cyclin D1 (a), 
Cdk4 (b), and procaspase-3 (c), in human DU145 prostate cancer cells. Western blots 
procedures were conducted on cell lysates and blots were detected by chemiluminescence 
and quantified using ImageJ software. Tukey’s multiple comparisons test was used to 
analyze significant variance between groups. Values are mean ± standard error of the 
mean (SEM), n = 3.
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CHAPTER V 
Discussion and Conclusions 
Building on previous studies showing the anti-proliferative, cell cycle arresting, 
and apoptotic effects of tocotrienols and xanthorrhizol in cancers of prostate, liver, breast, 
colon and skin, this thesis studied the synergistic effects of tocotrienol and xanthorrhizol 
in prostate cancer cells for the first time. Our cell proliferation data show a similar 
pattern, with decreased cell proliferation shown in cells treated with d-δ-tocotrienol and 
xanthorrhizol, individually and in combination. The combined treatments (T5/X32.5 and 
T10/X32.5) showed a significant decrease in cell viability compared to the control (no 
treatment). Proliferation of cells treated with d-δ-tocotrienol (T5, T10) was not 
significantly lower than the control, whereas individual treatment with xanthorrhizol 
(X32.5) led to cell proliferation significantly lower than that of the control. There was a 
significant decrease in groups T5/X32.5 and T10/X32.5 (p < 0.001), compared to group 
T10.  
These data suggest that combined treatments of d-δ-tocotrienol and xanthorrhizol 
may have a more potent impact on DU-145 cell viability compared to treatments of the 
two compounds alone. The X16.25 group showed inconsistent results in cell 
proliferation. Inadvertent variations in preparation of xanthorrhizol stock solution and 
density of inoculated DU-145 cells may have contributed to the variations. Additional 
studies are needed to more accurately determine the effect of xanthorrhizol on DU-145 
cell proliferation. The lack of consistent response with X16.25 treatment also precludes 
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the possibility of a CompuSyn analysis because a minimum of two concentrations of 
either compounds in a combination is required for the isobologram analysis. 
Cell cycle analysis showed no significant differences between any of the 
treatment groups and the control in the G1, S, and G2 phases with one exception; X32.5 
significantly reduced the percentage of cells in G2. Additionally, T5/X32.5 significantly 
increased the percentage of cells in S phase compared to X32.5. It is perplexing that 
X32.5 and T5/X16.25 caused opposite effect on the distribution of cells in the G2 phase. 
Literature has shown that tocotrienols induce G1/S arrest in human prostate (19) and 
melanoma (5) cancer cells and xanthorrhizol induces G1 and G2/M arrests in human 
colon cancer cells (21). The asynchronized cells that started in various phases of the cell 
cycle before treatments and the timing and length of the treatments may have caused 
some of the variations in these findings. Further studies are required to elucidate the 
effect of these compounds on cell cycle distribution in DU-145 cells.   
 The lack of consistent cell cycle arrest induced by the compounds may be 
congruent with western blot analysis finding no significant difference in Cdk4 and cyclin 
D1 levels between treatment groups and the control. Previous studies have shown that 
tocotrienols reduced Cdk4 expression in human melanoma cells. (5) Cell line-specific 
responses, different sources of antibodies, and technique-related variations in blot 
quantification may have led to the lack of detection of treatment effects. Additionally, 
varying treatment times may have affected cell response. Cell viability was assessed after 
72 hours of treatment, whereas cell cycle analysis and western blot lysate collection was 
conducted after 24 hours of treatment.  
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As one of the early events in initiating apoptosis, procaspase-3 is cleaved to a 
shorter but active caspase-3 that drives apoptosis. Treatments with T5/X16.25, T5/X32.5, 
and T10/X16.25 led to slight and non-significant decreases in the level of procaspase-3 
(87%, 77%, and 88%, respectively) when compared to the control (100%). This finding 
suggests that caspase-3 may be activated with combined treatments but that the doses of 
treatments may need to be altered to show a significant effect for the initiation of 
apoptosis.  
Data from this study showed a significant decrease in cell viability from 
individual and combined treatments of d-δ-tocotrienol and xanthorrhizol. However, we 
did not show significant down regulation of Cdk4 or cyclin D1 for induction of cell cycle 
arrest, or procaspase-3 activation for apoptosis initiation. Multiple explanations for these 
observations are possible. Firstly, changes in doses of d-δ-tocotrienol and xanthorrhizol 
in individual and combined treatments may increase their efficacies in downregulation of 
the proteins of interest. Secondly, d-δ-tocotrienol is a fat-soluble vitamin and may have 
contributed to the cellular uptake of xanthorrhizol.  
Third, detached cells were not used in any of the experiments described. After 
plating and treatment, some cells may detach before collection. Including detached cells 
for analysis may contribute to a larger sample size with a higher proportion of apoptotic 
cells with activation of pro-caspase-3.  
Fourth, using a colorimetric assay to detect caspase-3 activity in DU-145 cells 
may be assessed in future studies, providing a direct approach for detecting apoptosis. 
Other caspases may also provide insight to apoptosis as a potential mechanism of action. 
As previously mentioned, caspases 2, 8, and 9 are initiator caspases that cleave 
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downstream effectors caspases 3, 6, and 7. Effector caspases execute apoptosis by 
cleaving cellular proteins. Initiator and effector caspases may need to be studied 
simultaneously to determine if initiation and/or execution of apoptosis has occurred in 
DU-145 cells after individual and combined treatments of d-δ-tocotrienol and 
xanthorrhizol. 
Alternatively, suppression of cell proliferation may have been caused by other 
signaling pathways that also regulate cell growth. For example, d-δ-tocotrienol has been 
shown to decrease viability of prostate and esophageal cancer cells, respectively, by 
inhibiting nuclear factor kappa B cells (NF-kB) of the Akt/NF-kB pathway. NF-kB, a 
pro-inflammatory transcription factor, is an important regulator in cell survival. 
Downregulation of NF-kB decreases inflammation, thereby decreasing the chance of 
certain cancers. (16) 
In conclusion, combination of d-δ-tocotrienol and xanthorrhizol inhibited the 
growth of DU-145 cells with greater potencies than those of individual agents. Our 
limited studies did not show a significant change in cell cycle arrest or down regulation 
of Cdk4 and cyclin D1 in induction of cell cycle arrest, or activation of procaspase-3 for 
apoptosis initiation. Further studies are needed to confirm these results.  
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